|Bid||0.00 x 800|
|Ask||18.80 x 800|
|Day's Range||13.67 - 14.01|
|52 Week Range||10.25 - 26.05|
|Beta (3Y Monthly)||3.60|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Neurocrine (NBIX) collaborates with Jnana Therapeutics to develop novel small-molecule therapies for multiple targets of central nervous system (CNS) disorders.
GlycoMimetics (NASDAQ:GLYC) issued a second quarter earnings report that investors will like. Its cash position was at high enough levels to cover future operational needs. GlycoMimetics ended the second quarter (Jun. 30, 2018) with $229.4 million in cash.
On a per-share basis, the Rockville, Maryland-based company said it had a loss of 26 cents. The results beat Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment ...
The Rockville, Maryland-based company said it had a loss of 33 cents per share. The results did not meet Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research ...
The Rockville, Maryland-based company said it had a loss of 27 cents per share. The results missed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research ...
GlycoMimetics Inc’s (NASDAQ:GLYC): GlycoMimetics, Inc., a clinical stage biotechnology company, focuses on the discovery and development of glycomimetic drugs to address unmet medical needs resulting from diseases in the UnitedRead More...
GlycoMimetics (GLYC) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
Zero-debt allows substantial financial flexibility, especially for small-cap companies like GlycoMimetics Inc (NASDAQ:GLYC), as the company does not have to adhere to strict debt covenants. However, it also faces higherRead More...
There's talk that tax reform could give biotech M&A a kick-start. If it does, then investors will want to keep tabs on these stocks.
Assessing GlycoMimetics Inc’s (NASDAQ:GLYC) performance as a company requires looking at more than just a years’ earnings data. Below, I will run you through a simple sense check to buildRead More...
A wholly owned cancer drug could eventually reshape an important indication, and a new sickle-cell disease drug could be heading to the FDA as soon as next year.
GlycoMimetics defied a hematology biotech pitfall Tuesday, breaking out on strong cancer drug data.
The Zacks Analyst Blog Highlights: Sangamo Therapeutics, Sarepta Therapeutics, Akebia Therapeutics, Calithera Biosciences and GlycoMimetics
With the pharma and biotech sector bouncing back in 2017, here is a look at five drug stocks including Sarepta (SRPT) that are broker favorites.
GlycoMimetics Inc (NASDAQ:GLYC), a biotechnology company based in United States, saw a significant share price rise of over 20% in the past couple of months on the NasdaqGM. As aRead More...